NCT04296604 Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
| NCT ID | NCT04296604 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Traumatic Brain Injury |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2014-09 |
| Primary Completion | 2026-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 600 participants in total. It began in 2014-09 with a primary completion date of 2026-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In the current study, the investigators aim to understand the role of transcranial direct current stimulation (tDCS) in improving executive function across neuropsychiatric populations known to have deficits in this cognitive domain.
Eligibility Criteria
Inclusion Criteria 1. Male and female outpatients 18-65 years of age 2. A diagnosis of traumatic brain injury, major depressive disorder, bipolar disorder, schizophrenia, attention deficit hyperactivity disorder, borderline personality disorder and substance use disorders meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria. Exclusion Criteria 1. Contraindication to tDCS: history or epilepsy, metallic implants in the head and neck, brain stimulators, vagus nerve stimulators, shunts, pacemakers, pregnancy. 2. Active substance dependence (except for tobacco and cannabis). 3. Pregnant or nursing females. 4. Inability to participate in testing procedures. 5. Additional exclusion criteria for healthy controls: 1. Diagnosis of psychiatric of neurological disorder 2. Ongoing treatment with any psychotropic medications.
Contact & Investigator
Joan Camprodon, MD, PhD, MPH
📞 6177265348
Joan Camprodon, MD, PhD, MPH
PRINCIPAL INVESTIGATOR
Massachusetts General Hospital
Frequently Asked Questions
Who can join the NCT04296604 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Traumatic Brain Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04296604 currently recruiting?
Yes, NCT04296604 is actively recruiting participants. Visit ClinicalTrials.gov or contact Massachusetts General Hospital to inquire about joining.
Where is the NCT04296604 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT04296604 clinical trial?
NCT04296604 is sponsored by Massachusetts General Hospital. The principal investigator is Joan Camprodon, MD, PhD, MPH at Massachusetts General Hospital. The trial plans to enroll 600 participants.